{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-127004","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.475073+00:00","generated_at":"2026-05-29T05:19:27.606986+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333","bullets":["APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.","Phase 1 trial: double-blind, placebo-controlled, single-ascending dose in ~32 healthy volunteers across 4 cohorts.","Interim safety and pharmacokinetic data expected in second half of 2025.","Preclinical proof-of-concept achieved for APG777+APG333 combination; clinical trial planning underway in asthma and COPD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-127004","json":"https://secwatch.observer/filing/0001104659-24-127004.json","markdown":"https://secwatch.observer/filing/0001104659-24-127004.md","text":"https://secwatch.observer/filing/0001104659-24-127004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/0001104659-24-127004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/tm2430568d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:19:27.606986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}